Your session is about to expire
← Back to Search
Part 1: Dose Escalation and Safety Expansion for Small Cell Lung Cancer
Study Summary
This trial is testing a new drug called BG-68501 in patients with advanced solid tumors to see if it is safe, how the body processes it, its effects on the tumor, and its initial
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the recruitment phase for this medical study currently ongoing?
"According to clinicaltrials.gov, this investigation is currently seeking eligible individuals. The trial was initially listed on 2/28/2024 and most recently revised on 4/23/2024."
In how many locations is this trial currently being conducted?
"There are a total of 5 active facilities participating in this trial, such as Titan Health Partners Llc Dba Astera Cancer Care located in East Brunswick, Mary Crowley Cancer Research based in Dallas, and Genesiscare North Shore situated in St Leonards, alongside additional sites."
What is the level of risk associated with Phase 1: Dosage Increase and Safety Expansion for individuals?
"Given the limited safety and efficacy data available for Part 1: Dose Escalation and Safety Expansion, it has been rated a 1 on our internal scale at Power. This aligns with its Phase 1 trial status."
Share this study with friends
Copy Link
Messenger